Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants.
Standard
Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. / Mühlbacher, A; Weber, Beatrice; Bürgisser, P; Eiras, A; Cabrera, J; Louisirirotchanakul, S; Tiller, F-W; Kim, H-S; V Helden, J; Bossi, V; Echevarria, J-M.
in: MED MICROBIOL IMMUN, Jahrgang 197, Nr. 1, 1, 2008, S. 55-64.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants.
AU - Mühlbacher, A
AU - Weber, Beatrice
AU - Bürgisser, P
AU - Eiras, A
AU - Cabrera, J
AU - Louisirirotchanakul, S
AU - Tiller, F-W
AU - Kim, H-S
AU - V Helden, J
AU - Bossi, V
AU - Echevarria, J-M
PY - 2008
Y1 - 2008
N2 - In a multicenter study a new, fully automated Roche Diagnostics Elecsys HBsAg II screening assay with improved sensitivity to HBsAg mutant detection was compared to well-established HBsAg tests: AxSYM HBsAg V2 (Abbott), Architect HBsAg (Abbott), Advia Centaur HBsAg (Bayer) Enzygnost HBsAg 5.0 (Dade-Behring), and Vitros Eci HBsAg (Ortho). A total of 16 seroconversion panels, samples of 60 HBsAg native mutants, and 31 HBsAg recombinant mutants, dilution series of NIBSC and PEI standards, 156 HBV positive samples comprising genotypes A to G, 686 preselected HBsAg positive samples from different stages of infection, 3,593 samples from daily routine, and 6,360 unselected blood donations were tested to evaluate the analytical and clinical sensitivity, the detection of mutants, and the specificity of the new assay. Elecsys HBsAg II showed a statistically significant better sensitivity in seroconversion panels to the compared tests. Fifty-seven out of 60 native mutants and all recombinant mutants were found positive. Among 156 HBV samples with different genotypes and 696 preselected HBsAg positive samples Elecsys HBsAg II achieved a sensitivity of 100%. The lower detection limit for NIBSC standard was calculated to be 0.025 IU/ml and for the PEI standards ad and ay it was
AB - In a multicenter study a new, fully automated Roche Diagnostics Elecsys HBsAg II screening assay with improved sensitivity to HBsAg mutant detection was compared to well-established HBsAg tests: AxSYM HBsAg V2 (Abbott), Architect HBsAg (Abbott), Advia Centaur HBsAg (Bayer) Enzygnost HBsAg 5.0 (Dade-Behring), and Vitros Eci HBsAg (Ortho). A total of 16 seroconversion panels, samples of 60 HBsAg native mutants, and 31 HBsAg recombinant mutants, dilution series of NIBSC and PEI standards, 156 HBV positive samples comprising genotypes A to G, 686 preselected HBsAg positive samples from different stages of infection, 3,593 samples from daily routine, and 6,360 unselected blood donations were tested to evaluate the analytical and clinical sensitivity, the detection of mutants, and the specificity of the new assay. Elecsys HBsAg II showed a statistically significant better sensitivity in seroconversion panels to the compared tests. Fifty-seven out of 60 native mutants and all recombinant mutants were found positive. Among 156 HBV samples with different genotypes and 696 preselected HBsAg positive samples Elecsys HBsAg II achieved a sensitivity of 100%. The lower detection limit for NIBSC standard was calculated to be 0.025 IU/ml and for the PEI standards ad and ay it was
M3 - SCORING: Zeitschriftenaufsatz
VL - 197
SP - 55
EP - 64
JO - MED MICROBIOL IMMUN
JF - MED MICROBIOL IMMUN
SN - 0300-8584
IS - 1
M1 - 1
ER -
